Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Launch Date: October 1, 2024

Release Date: October 1, 2024

Expiration Date: September 30, 2025

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Chief Medical Officer, Internat ...